FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
03 Giugno 2024 - 1:00PM
FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig,
Chief Executive Officer, will participate in a Fireside Chat at
Goldman Sachs 45th Annual Global Healthcare Conference to be held
in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM
Eastern Time. Company management will also participate in
one-on-one meetings with investors during the conference.
A live audio webcast of the event will be
available to investors and other interested parties on the “Events
& Presentations” section of the FibroGen Investor webpage at
www.fibrogen.com. A replay will be available for 90 days.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company focused on accelerating the development
of novel therapies at the frontiers of cancer biology. Pamrevlumab,
a fully human anti-CTGF monoclonal antibody, is in clinical
development for the treatment of metastatic pancreatic cancer and
locally advanced unresectable pancreatic cancer (LAPC). Roxadustat
(爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan,
and numerous other countries for the treatment of anemia in chronic
kidney disease (CKD) patients on dialysis and not on dialysis.
Roxadustat is in clinical development for chemotherapy-induced
anemia (CIA) and a Supplemental New Drug Application (sNDA) has
been accepted for review by the China Health Authority. FG-3246
(also known as FOR46), a first-in-class antibody-drug conjugate
(ADC) targeting CD46 is in development for the treatment of
metastatic castration-resistant prostate cancer. This program also
includes the development of an associated CD46-targeted PET
biomarker. In addition, FibroGen has expanded its research and
development portfolio to include two immuno-oncology product
candidates for the treatment of solid tumors. For more information,
please visit www.fibrogen.com.
Contacts:FibroGen, Inc.
Investors:David DeLucia, CFAVice President of
Corporate FP&A / Investor Relationsir@fibrogen.com
Media:Simon MillerCommercial and External
Communicationsmedia@fibrogen.com
Grafico Azioni FibroGen (NASDAQ:FGEN)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni FibroGen (NASDAQ:FGEN)
Storico
Da Gen 2024 a Gen 2025